

Herbert Pang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6174411/publications.pdf>

Version: 2024-02-01

68
papers

2,761
citations

279701

23
h-index

182361

51
g-index

70
all docs

70
docs citations

70
times ranked

4513
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. Chinese Clinical Oncology, 2022, 11, 7-7.	0.4	1
2	Assessing surrogacy using restricted mean survival time ratio for overall survival in liver cancer immunotherapy studies.. Journal of Clinical Oncology, 2022, 40, e16222-e16222.	0.8	0
3	Role of dietary carbohydrates on risk of lung cancer. Lung Cancer, 2021, 155, 87-93.	0.9	16
4	Pathway-Based Single-Cell RNA-Seq Classification, Clustering, and Construction of Gene-Gene Interactions Networks Using Random Forests. IEEE Journal of Biomedical and Health Informatics, 2020, 24, 1814-1822.	3.9	13
5	Bacteriophage of the Skin Microbiome in Patients with Psoriasis and Healthy Family Controls. Journal of Investigative Dermatology, 2020, 140, 182-190.e5.	0.3	19
6	Tuberculosis infection and lung adenocarcinoma: Mendelian randomization and pathway analysis of genome-wide association study data from never-smoking Asian women. Genomics, 2020, 112, 1223-1232.	1.3	15
7	Pathway-based meta-analysis for partially paired transcriptomics analysis. Research Synthesis Methods, 2020, 11, 123-133.	4.2	0
8	Determinants of physical, mental and social well-being: a longitudinal environment-wide association study. International Journal of Epidemiology, 2020, 49, 380-389.	0.9	23
9	Development and Validation of a Natural Language Processing Tool to Generate the CONSORT Reporting Checklist for Randomized Clinical Trials. JAMA Network Open, 2020, 3, e2014661.	2.8	3
10	An enhanced machine learning tool for cis eQTL mapping with regularization and confounder adjustments. Genetic Epidemiology, 2020, 44, 798-810.	0.6	0
11	Endpoint surrogacy in oncology Phase 3 randomised controlled trials. British Journal of Cancer, 2020, 123, 333-334.	2.9	8
12	Preventing Respiratory Tract Infections by Synbiotic Interventions: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Advances in Nutrition, 2020, 11, 979-988.	2.9	51
13	Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. Lung Cancer, 2020, 141, 14-20.	0.9	9
14	Effect of machine learning re-sampling techniques for imbalanced datasets in 18F-FDG PET-based radiomics model on prognostication performance in cohorts of head and neck cancer patients. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2826-2835.	3.3	54
15	Diffusion-weighted magnetic resonance imaging of primary cervical cancer in the detection of sub-centimetre metastatic lymph nodes. Cancer Imaging, 2020, 20, 27.	1.2	4
16	Reporting and guidelines for mendelian randomization analysis: A systematic review of oncological studies. Cancer Epidemiology, 2019, 62, 101577.	0.8	16
17	Radiomics Model to Predict Early Progression of Nonmetastatic Nasopharyngeal Carcinoma after Intensity Modulation Radiation Therapy: A Multicenter Study. Radiology: Artificial Intelligence, 2019, 1, e180075.	3.0	32
18	Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies. Journal of Biopharmaceutical Statistics, 2019, 29, 592-605.	0.4	4

#	ARTICLE	IF	CITATIONS
19	Change in moderate alcohol consumption and quality of life: evidence from 2 population-based cohorts. <i>Cmaj</i> , 2019, 191, E753-E760.	0.9	5
20	Clinical prognostic model for older patients with advanced non-small cell lung cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 555-559.	0.5	6
21	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. <i>Cancer</i> , 2019, 125, 382-390.	2.0	14
22	A Phase I Trial of the IGF-1R Antibody Ganitumab (AMG 479) in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer. <i>Oncologist</i> , 2018, 23, 782-790.	1.9	19
23	Analysis of 7,815 cancer exomes reveals associations between mutational processes and somatic driver mutations. <i>PLoS Genetics</i> , 2018, 14, e1007779.	1.5	44
24	Modulation of Circulating Protein Biomarkers in Cancer Patients Receiving Bevacizumab and the Anti-Endoglin Antibody, TRC105. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2248-2256.	1.9	17
25	Cohort Profile: FAMILY Cohort. <i>International Journal of Epidemiology</i> , 2017, 46, e1-e1.	0.9	58
26	Longitudinal Patterns and Predictors of Depression Trajectories Related to the 2014 Occupy Central/Umbrella Movement in Hong Kong. <i>American Journal of Public Health</i> , 2017, 107, 593-600.	1.5	46
27	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. <i>Oncologist</i> , 2017, 22, 189-198.	1.9	9
28	Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. <i>Lung Cancer</i> , 2017, 114, 79-89.	0.9	17
29	A comparison of graph- and kernel-based omics data integration algorithms for classifying complex traits. <i>BMC Bioinformatics</i> , 2017, 18, 539.	1.2	26
30	Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 2249-2260.	1.3	19
31	Bayesian Semiparametric Model for Pathway-Based Analysis with Zero-Inflated Clinical Outcomes. <i>Journal of Agricultural, Biological, and Environmental Statistics</i> , 2016, 21, 641-662.	0.7	3
32	Composition of gut microbiota in infants in China and global comparison. <i>Scientific Reports</i> , 2016, 6, 36666.	1.6	63
33	Direct Participation in and Indirect Exposure to the Occupy Central Movement and Depressive Symptoms: A Longitudinal Study of Hong Kong Adults. <i>American Journal of Epidemiology</i> , 2016, 184, 636-643.	1.6	25
34	Seamless Phase IIa/IIb and enhanced dose-finding adaptive design. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 912-923.	0.4	6
35	Shrinkage-based diagonal Hotelling's tests for high-dimensional small sample size data. <i>Journal of Multivariate Analysis</i> , 2016, 143, 127-142.	0.5	22
36	Normative data and psychometric properties of the Connor-Davidson Resilience Scale (CD-RISC) and the abbreviated version (CD-RISC2) among the general population in Hong Kong. <i>Quality of Life Research</i> , 2016, 25, 111-116.	1.5	76

#	ARTICLE	IF	CITATIONS
37	Statistical aspect of translational and correlative studies in clinical trials. Chinese Clinical Oncology, 2016, 5, 11.	0.4	1
38	A leave-one-out cross-validation SAS macro for the identification of markers associated with survival. Computers in Biology and Medicine, 2015, 57, 123-129.	3.9	45
39	VATS Lobectomy Has Better Perioperative Outcomes Than Open Lobectomy: CALGB 31001, an Ancillary Analysis of CALGB 140202 (Alliance). Annals of Thoracic Surgery, 2015, 99, 399-405.	0.7	170
40	A Phase I/biomarker study of bevacizumab in combination with CNTO 95 in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology, 2015, 75, 343-352.	1.1	7
41	Biomarker Signatures Correlate with Clinical Outcome in Refractory Metastatic Colorectal Cancer Patients Receiving Bevacizumab and Everolimus. Molecular Cancer Therapeutics, 2015, 14, 1048-1056.	1.9	22
42	Direct Evidence of Target Inhibition with Anti-VEGF, EGFR, and mTOR Therapies in a Clinical Model of Wound Healing. Clinical Cancer Research, 2015, 21, 3442-3452.	3.2	5
43	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. Lung Cancer, 2015, 90, 281-287.	0.9	6
44	Random Effects Model for Multiple Pathway Analysis with Applications to Type II Diabetes Microarray Data. Statistics in Biosciences, 2015, 7, 167-186.	0.6	8
45	Stratified Pathway Analysis to Identify Gene Sets Associated with Oral Contraceptive Use and Breast Cancer. Cancer Informatics, 2014, 13s4, CIN.S13973.	0.9	3
46	Integrative Pathway Analysis Using Graph-Based Learning with Applications to TCGA Colon and Ovarian Data. Cancer Informatics, 2014, 13s4, CIN.S13634.	0.9	6
47	Transmissibility of the Ice Bucket Challenge among globally influential celebrities: retrospective cohort study. BMJ, The, 2014, 349, g7185-g7185.	3.0	11
48	Methodological Considerations in the Design and Implementation of Clinical Trials. Seminars in Oncology Nursing, 2014, 30, 74-79.	0.7	3
49	Modulation of circulating protein biomarkers following TRC 105 (anti- ϵ -endoglin antibody) treatment in patients with advanced cancer. Cancer Medicine, 2014, 3, 580-591.	1.3	27
50	Phase I study of capecitabine, oxaliplatin, bevacizumab, and everolimus in advanced solid tumors. Investigational New Drugs, 2014, 32, 700-709.	1.2	4
51	Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Medicine, 2013, 2, 234-242.	1.3	64
52	Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy. JAMA - Journal of the American Medical Association, 2013, 309, 1359.	3.8	785
53	Block-diagonal discriminant analysis and its bias-corrected rules. Statistical Applications in Genetics and Molecular Biology, 2013, 12, 347-59.	0.2	4
54	Prognostic and Predictive Blood-Based Biomarkers in Patients with Advanced Pancreatic Cancer: Results from CALGB80303 (Alliance). Clinical Cancer Research, 2013, 19, 6957-6966.	3.2	95

#	ARTICLE	IF	CITATIONS
55	Sample Size Considerations of Prediction Validation Methods in High-Dimensional Data for Survival Outcomes. Genetic Epidemiology, 2013, 37, 276-282.	0.6	29
56	Phase II Study of Induction Cisplatin and Irinotecan Followed by Concurrent Carboplatin, Etoposide, and Thoracic Radiotherapy for Limited-Stage Small-Cell Lung Cancer, CALGB 30206. Journal of Thoracic Oncology, 2013, 8, 102-108.	0.5	23
57	A Pooled Analysis of Limited-Stage Small-Cell Lung Cancer Patients Treated with Induction Chemotherapy Followed by Concurrent Platinum-Based Chemotherapy and 70 Gy Daily Radiotherapy: CALGB 30904. Journal of Thoracic Oncology, 2013, 8, 1043-1049.	0.5	49
58	Phase II Study of Dasatinib in Patients with Previously Treated Malignant Mesothelioma (Cancer and) Tj ETQq0 0 0 ggBT /Overlock 10 Tf	0.5	59
59	Gene Selection Using Iterative Feature Elimination Random Forests for Survival Outcomes. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 2012, 9, 1422-1431.	1.9	54
60	Bayesian semiparametric regression models for evaluating pathway effects on continuous and binary clinical outcomes. Statistics in Medicine, 2012, 31, 1633-1651.	0.8	16
61	Pathway-based identification of SNPs predictive of survival. European Journal of Human Genetics, 2011, 19, 704-709.	1.4	19
62	A Phase II Trial of Bevacizumab plus Everolimus for Patients with Refractory Metastatic Colorectal Cancer. Oncologist, 2011, 16, 1131-1137.	1.9	58
63	A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307. Journal of Thoracic Oncology, 2010, 5, 1655-1661.	0.5	115
64	Analysing breast cancer microarrays from African Americans using shrinkage-based discriminant analysis. Human Genomics, 2010, 5, 5.	1.4	4
65	Pathway analysis using random forests with bivariate node-split for survival outcomes. Bioinformatics, 2010, 26, 250-258.	1.8	38
66	Shrinkage-based Diagonal Discriminant Analysis and Its Applications in High-Dimensional Data. Biometrics, 2009, 65, 1021-1029.	0.8	48
67	Building pathway clusters from Random Forests classification using class votes. BMC Bioinformatics, 2008, 9, 87.	1.2	28
68	Pathway analysis using random forests classification and regression. Bioinformatics, 2006, 22, 2028-2036.	1.8	210